MedifastMED
MED
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
24% more call options, than puts
Call options by funds: $7.05M | Put options by funds: $5.68M
2.72% less ownership
Funds ownership: 84.29% [Q3] → 81.57% (-2.72%) [Q4]
9% less funds holding
Funds holding: 140 [Q3] → 128 (-12) [Q4]
11% less capital invested
Capital invested by funds: $177M [Q3] → $157M (-$19.3M) [Q4]
24% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 46
38% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 29
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16.50
27%
upside
Avg. target
$16.50
27%
upside
High target
$16.50
27%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
DA Davidson Linda Bolton Weiser 23% 1-year accuracy 24 / 105 met price target | 27%upside $16.50 | Neutral Maintained | 19 Feb 2025 |
Financial journalist opinion
Negative
Seeking Alpha
4 days ago
Medifast: GLP-1 Caused A Vicious MLM Flywheel Effect
Medifast, Inc.'s business is deteriorating as GLP-1 medication has lowered demand, causing a vicious flywheel effect as coaches are exiting the platform. The company is trying to reposition itself as a GLP-1 adjacent business, but the repositioning hasn't shown results so far with a deteriorating immediate earnings outlook. MED stock now trades below the company's net cash position, but due to high earnings uncertainty, the low valuation is justified.

Neutral
Zacks Investment Research
1 month ago
MED Q4 Earnings Beat, Revenues Dip Y/Y on Lower Customer Acquisition
Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.

Neutral
Seeking Alpha
1 month ago
Medifast, Inc. (MED) Q4 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.

Positive
Zacks Investment Research
1 month ago
Medifast (MED) Q4 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.

Neutral
Business Wire
1 month ago
Medifast Announces Fourth Quarter and Full Year 2024 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Revenue of $119.0 million, with revenue per active earning coach of $4,391 Independent active earning OPTAVIA coaches of 27,100 Net income of $0.8 million (non-GAAP adjusted net income of $1.1 million) Earnings per diluted share ("EPS") of.

Neutral
Business Wire
1 month ago
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2024 on Tuesday, February 18, 2025, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chie.

Neutral
Zacks Investment Research
2 months ago
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.

Neutral
Zacks Investment Research
2 months ago
Medifast Launches OPTAVIA ASCEND for Weight Loss Management
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.

Neutral
Business Wire
2 months ago
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND™ For GLP-1 Users & Those Looking for Help to Keep Weight Off
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE:MED), the health and wellness company known for its habit based and coach-guided lifestyle solution OPTAVIA, today announced OPTAVIA ASCEND — a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle hea.

Neutral
Business Wire
3 months ago
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessar.

Charts implemented using Lightweight Charts™